Jupiter Orphan Therapeutics Is Joined By Peter Elliott, Ph.D. And Ian Baker-Finch

JUPITER, Fla., Nov. 1, 2016 /PRNewswire/ -- Jupiter Orphan Therapeutics, Inc. (JOT) today announced that Peter Elliott, Ph.D. has joined JOT as a Scientific Advisor and Ian Baker-Finch as the company's Sports Ambassador.

Logo - http://photos.prnewswire.com/prnh/20161031/434558LOGO

"Fantastic addition to Jupiter Orphan Therapeutics to get such an experienced and successful scientist and product developer as Peter Elliott on board. His experience in product development, especially with Resveratrol, clinical trials and approval process has already assisted us in preparation for an upcoming FDA meeting," stated JOT CEO, Christer Rosén. 

Mr. Rosén further stated, "Ian Baker-Finch is a true professional not only in golf but in corporate commitments and dealing with the general public. Ian will play a role in JOT's social commitment in various future events educating the public about rare diseases as well as support of patient's organizations. His Australian background also fits well with our broad Australian connection such as Murdoch Childrens Research Institute."

Peter Elliott, Ph.D. is a Scientific Advisor at JOT. Peter holds a B.Sc. in Pharmacology from London University and a Ph. D. in Psychopharmacology from Cambridge University. After his post docs at Duke, Yale, and McGill, Peter joined the Glaxo Group Research for 5 years, leading to a number of CNS programs focusing on movement disorders, neurodegeneration as well as pain. Peter then moved back to the USA to enter biotech at Alkermes in Cambridge, MA, as Director of Pharmacology. After his time there, he moved on to ProScript which was acquired by LeukoSite, and ultimately Millennium, where he became Vice President of Pharmacology and Development. During his time there, he was a co-developer of the multiple myeloma drug, Velcade© and PS-519 for stroke. He later moved on to join CominatoRx where he was Executive Vice President of Product Development, and led the efforts resulting in 8 Phase II programs in inflammation and oncology. Peter was then Senior Vice President of R&D at Sirtris Pharmaceuticals. As part of work from his teams, three SIRT1 activators entered clinical development, SRT501, SRT2104 and SRT2379. He was also an integral part of the road-show to take Sirtris public with a successful IPO in 2007, leading to it being purchased by GSK in 2008 for $720M.

Ian Baker-Finch is the Sports Ambassador at JOT. He is a professional golfer, notably winning The Open Championship at Royal Birkdale in 1991. Mr. Baker-Finch retired from professional golf in 1997 after winning 17 times on multiple tours around the world. He ventured on to become an expert golf analyst, working for CBS on their PGA Tour coverage, including The Masters and US PGA Championship. After 20 years in sports television, Ian is highly regarded as one of the most popular and successful commentators and is known for his easy going manner and love for the game of golf. Mr. Baker- Finch has also been involved in the design of golf courses around the world for the last two decades, stating that the "Desert Course" at Arabian Ranches in Dubai as one of his proudest design achievements. Mr. Baker-Finch has been a Co-Captain once and Assistant Captain multiple times for the International President's Cup Team. Along with his course design business and television work, Ian has become one of the most popular corporate presenters, hosting golf days for many leading corporations and charities all over the world. A life member of the PGA of Australia, Ian is also a passionate advocate for the continued growth of the game within Australia and abroad and is a "Life Member" and former Director of the PGA Tour of Australasia. Mr. Baker-Finch has also been recognized by the Australian Government in 2000 as a recipient of the Australian Sports medal and was appointed Golf Team Leader for the Australian Olympic golf teams, both men and women's for the 2016 RIO Olympics.

Jupiter Orphan Pharmaceuticals, Inc., www.jupiterorphan.com, was formed to address rare diseases caused by, or related to, single gene deficiencies.

Visit www.jupiterorphan.com for additional company information.

Media contact:
Jupiter Orphan Therapeutics - +1 561 510-4877
131482@email4pr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/jupiter-orphan-therapeutics-inc-is-joined-by-peter-elliott-phd-and-ian-baker-finch-300354701.html

SOURCE Jupiter Orphan Therapeutics, Inc.